Drug Profile
SRX 3225
Alternative Names: BRD4/HDAC6/PI3K Triple Inhibitor - SignalRx; HDAC6/BRD4/PI3K Triple Inhibitor - SignalRx; PI3K/BRD4/HDAC6 Triple Inhibitor - SignalRx; SRX3225Latest Information Update: 28 Feb 2022
Price :
$50
*
At a glance
- Originator SignalRx Pharmaceuticals
- Class Antineoplastics; Small molecules
- Mechanism of Action 1 Phosphatidylinositol 3 kinase inhibitors; BRD4 protein inhibitors; HDAC6 protein inhibitors
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes - Cancer
Highest Development Phases
- No development reported Cancer
Most Recent Events
- 28 Feb 2022 No recent reports of development identified for research development in Cancer in USA
- 04 Jan 2018 SRX 3225 is available for licensing as of 04 Jan 2018. http://www.signalrx.com/
- 04 Jan 2018 Early research in Cancer in USA